Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma

J Surg Oncol. 1995 Jul;59(3):204-8. doi: 10.1002/jso.2930590314.

Abstract

Pancreatic cancer and jejunal cancer are aggressive diseases with grim prognoses. The long term survival of pancreatic carcinoma is still one of the worst of all cancers. Ninety-five percent of the patients die of their disease within 5 years [Wagener et al: Ann Oncol 5(Suppl 3): S87-S90, 1994]. Eighty-five percent of patients with jejunal carcinoma die of their disease within 5 years [Lioe, Biggart: J Clin Pathol 43:533-536, 1990]. To date, there are disappointingly few effective cytotoxic agents in the treatment of these cancers. We present a case of advanced-stage pancreatic carcinoma and a case of advanced stage jejunal carcinoma, each showing marked response to Taxol and platinum chemotherapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Female
  • Humans
  • Jejunal Neoplasms / drug therapy*
  • Jejunal Neoplasms / pathology
  • Middle Aged
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / secondary
  • Paclitaxel / administration & dosage
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / surgery

Substances

  • Paclitaxel
  • Cisplatin